Matthew Mintz, M.D. 
Off-Label Promotion Versus “Not on the Label”
It continues to become increasingly more difficult for pharmaceutical companies to use field-based representatives ...
Not All Doctors Hate DTC TV Ads
Back in November, the American Medical Association (AMA), the largest association of physicians in ...
Rise in Prior Authorizations Puts Doctors Off Brands
For many years, insurers have used prior authorizations for prescription medications. When formulary tiers ...
Why Doctors Quit or Stay
Recently, a political piece in the Washington Post entitled “Why Doctors Quit,” focused primarily ...
Physician Prescription Influence
Physician conflict of interest has been a concern since the time of Hippocrates. However, ...
Sell Your Company—Not Just Your Products
I was recently at a pharmaceutical company’s speaker’s training meeting. Having served as a ...
How Pharma Can Adjust to Primary Care’s Future Today
Drastic change is overtaking primary care. However, how pharma markets to primary care physicians ...
Adherence: The Next “Blockbuster”
While the day of the blockbuster pill died with Lipitor going generic, the days ...
Taking the Doctor Out of the Equation
As influential as the pharmaceutical industry can be, the most influential player in prescription ...
Is There a Doctor In-House?
A combination of conflict of interest concerns, public disclosure via the Sunshine Act and—particularly ...
Speaker Programs: RIP
On Tuesday, December 17th, 2013, GlaxoSmithKline, the sixth-largest global drug maker, announced that it ...
One Physician’s View on Drug Co-pay Cards
Discounts are a staple of the American culture. The Sunday section of almost every ...
